Curr Pharm Des. 2019 Jul 8. Epub 2019 Jul 8. PMID: 31298148
Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?
Diabetes Mellitus (DM) is now a well-known factor which initiates many metabolic derangements in various tissues and organs including liver, muscle, pancreas, adipose tissue, cardiovascular and nervous system. Cardiovascular complications are most important, and they are so intensively affected that their derangement leads to cardiac failure even in the absence of ischemic heart diseases. This entity of cardiac pathology in DM is often regarded as diabetic cardiomyopathy (DCM). Recently many plant derived drugs have been tested to control and alleviate DCM. Wogonin is one of the drugs whose characteristics has intensely been studied. Wogonin is a flavonoid which means they have yellow color pigment in their leaves and is obtained from the roots of plant Scutellaria Baicalensis Georgi. Wogonin has long been used as an active anti-cancer drug in Chinese medicine practice. In recent past wogonin has shown to possess notable anti-inflammatory, anti-allergic properties also. Wogonin has demonstrated to possess anti-oxidant, anti-viral, anti-inflammatory and also anti-thrombotic properties. Wogonin has shown to alleviate apoptosis, and ER stress in the cells and this property can also be used in the treatment of cardiovascular diseases. Notably, Wogonin has been documented to have an extensive margin of safety as well as displays little or no organ toxicity following extended intravenous administration. In this review we have discussed recently discovered therapeutic potential of wogonin in the treatment of DCM.